The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Ebglyss (lebrikizumab) for the treatment of moderate-to-severe eczema, also known as atopic dermatitis, in adult and pediatric patients 12 years and older. This approval marks a significant advancement in the treatment landscape for individuals whose eczema symptoms are not adequately controlled by topical medications or other systemic treatments. The injectable medication is expected to be available in the coming weeks.
Mechanism of Action and Clinical Efficacy
Ebglyss is a monoclonal antibody that selectively targets and neutralizes the interleukin-13 (IL-13) protein, a key driver of eczema progression. The FDA's decision was supported by data from three clinical studies involving over 1,000 patients with moderate-to-severe eczema. These studies demonstrated that Ebglyss significantly reduced the severity and extent of eczema symptoms in patients who had not responded well to topical treatments. Dr. Jonathan Silverberg, professor of dermatology at George Washington University School of Medicine and Health Sciences, highlighted the approval as "a big win for patients," offering a new first-line biologic treatment option.
Dosing and Administration
One potential advantage of Ebglyss is its less frequent dosing schedule compared to some existing treatments. While Dupixent, another biologic treatment for eczema, requires twice-monthly injections for adults, Ebglyss can be administered once monthly. This less frequent dosing regimen may improve patient adherence and convenience, as noted by Jefferies analyst Lucy Codrington.
Eczema: A Significant Health Burden
Eczema affects approximately 16.5 million adults in the United States, according to the National Eczema Association. The chronic inflammatory skin condition is characterized by itching, rashes, and dry patches, significantly impacting patients' quality of life. While several treatments are available, including AbbVie's Rinvoq, Pfizer's Cibinqo, and Sanofi and Regeneron's Dupixent, the approval of Ebglyss provides an additional option for patients who may not respond adequately to existing therapies.
Regulatory History and Market Availability
In the previous year, the FDA had declined to approve Ebglyss due to findings from an inspection of a contract manufacturer. However, these issues have been resolved, paving the way for the drug's approval and subsequent availability in the U.S. Ebglyss is already approved for use in Europe and Japan, with further market expansions anticipated later in the year.
